PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
805.21%
Some net income increase while CRON.TO is negative at -81.36%. John Neff would see a short-term edge over the struggling competitor.
-1.20%
Both reduce yoy D&A, with CRON.TO at -18.43%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-144.47%
Negative yoy deferred tax while CRON.TO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-31.19%
Negative yoy SBC while CRON.TO is 63.04%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-216.50%
Negative yoy working capital usage while CRON.TO is 61.18%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-125.33%
Both yoy AR lines negative, with CRON.TO at -114.68%. Martin Whitman would suspect an overall sector lean approach or softer demand.
-1216.66%
Negative yoy inventory while CRON.TO is 191.26%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
No Data
No Data available this quarter, please select a different quarter.
61.39%
Lower 'other working capital' growth vs. CRON.TO's 1007.34%. David Dodd would see fewer unexpected short-term demands on cash.
-38.83%
Negative yoy while CRON.TO is 310.13%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-170.95%
Negative yoy CFO while CRON.TO is 22.54%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
38.81%
CapEx growth well above CRON.TO's 14.70%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
474.30%
Growth well above CRON.TO's 101.99%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
85.28%
We have mild expansions while CRON.TO is negative at -196.82%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
3.34%
Debt repayment growth of 3.34% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
No Data
No Data available this quarter, please select a different quarter.
125.12%
Repurchase growth 1.25-1.5x CRON.TO's 91.12%. Bruce Berkowitz would confirm if the firm invests enough in expansions while boosting EPS.